NPPA revises ceiling prices of 128 formulations
The National Pharmaceutical Pricing Authority (NPPA) has also fixed the retail price of 12 scheduled formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022). The retail price of one tablet of anti-diabetes combination drug Glimepiride, Voglibose& Metformin (extended release) has been fixed at Rs 13.83. Similarly, retail price of one tablet of Paracetamol, Phenylephrine Hydrochloride, Diphenhydramine Hydrochloride and Caffeine has been fixed at Rs 2.76. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 16, 2023 Category: Pharmaceuticals Source Type: news
Is Glimepiride a Safer Sulfonylurea for Type 2 Diabetes? Is Glimepiride a Safer Sulfonylurea for Type 2 Diabetes?
Observational data show that certain types of sulfonylureas for the treatment of type 2 diabetes are associated with more cardiovascular events compared to other types, such as glimepiride.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 22, 2022 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
Glucose-Lowering Meds Compared for Use With Metformin in T2DM
MONDAY, Oct. 3, 2022 -- For patients with type 2 diabetes receiving metformin, the addition of glargine and liraglutide is more effective than glimepiride and sitagliptin for achieving and maintaining target glycated hemoglobin levels, while the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 3, 2022 Category: Pharmaceuticals Source Type: news
GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin
The US-funded GRADE trial shows liraglutide performed best overall when added to metformin, followed by insulin glargine, with sitagliptin and glimepiride trailing. But SGLT2 inhibitors were not included in study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 21, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
NPPA fixes price caps for 12 anti-diabetic medicines
These include glimepiride tablet of strength 1 mg, with ceiling price at Rs 3.6 per tablet, while that for 2 mg is Rs 5.72 per tablet. The ceiling price of 1 ml glucose injection of 25 per cent strength has been fixed at 17 paise, while that of 1ml of insulin (soluble) injection of strength 40IU/ml is Rs 15.09. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 25, 2021 Category: Pharmaceuticals Source Type: news
CAROLINA-CARMELINA-Asia-analysis
Cardiovascular and renal safety profile of linagliptin demonstrated in Asian adults with type 2 diabetesIn a sub-analysis of the CAROLINA ® cardiovascular outcome trial, linagliptin demonstrated no increased cardiovascular risk versus glimepiride in Asian adults with type 2 diabetes and high cardiovascular risk1In addition, a sub-analysis of the CARMELINA ® cardiovascular outcome trial demonstrated a similar cardiovascular and renal safety profile for linagliptin versus placebo in Asian adults with type 2 diabetes and high cardiorenal risk2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 29, 2020 Category: Research Source Type: news
CAROLINA Published: Reaffirms Sulfonylurea Cardiovascular Safety CAROLINA Published: Reaffirms Sulfonylurea Cardiovascular Safety
The study, presented to a European audience of diabetologists at EASD and simultaneously published in JAMA, reaffirms the CV safety of glimepiride, with calls for FDA warning to be removed.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 20, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Linagliptin Noninferior for CV Risk in Early Type 2 Diabetes
THURSDAY, Sept. 19, 2019 -- Linagliptin is noninferior to glimepiride for adults with relatively early type 2 diabetes and elevated cardiovascular risk, according to a study published online Sept. 19 in the Journal of the American Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 19, 2019 Category: Pharmaceuticals Source Type: news
Medical News Today: What to know about glimepiride
Glimepiride is a drug people use to control blood sugar levels in type 2 diabetes. Find out about the potential side effects of glimepiride, and the possible risks of taking this drug. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 23, 2019 Category: Consumer Health News Tags: Diabetes Type 2 Source Type: news
CAROLINA Reassures on CV Safety for Linagliptin, Glimepiride in T2D CAROLINA Reassures on CV Safety for Linagliptin, Glimepiride in T2D
"We think we ' ve vindicated sulfonylureas, at least glimepiride specifically," says an expert, who notes trial findings do inform decision-making, particularly when cost is an issue.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 12, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta®
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk.(1) The findings were reported today at the American Diabetes Association's 79th Scientific Sessions in San Francisco. (Source: World Pharma News)
Source: World Pharma News - June 11, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news
CAROLINA-full-data
Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta®CAROLINA ® demonstrated no increased cardiovascular risk for Trajenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor Adults with diabetes treated with Trajenta ® experienced significantly fewer events of hypoglycaemia and a modest weight reduction compared to patients treated with glimepiride Detailed results from CAROLINA ® were presented at the American Diabetes Association’s 79th Scientific Sessions (Source: Boehringer...
Source: Boehringer Ingelheim Corporate News - June 11, 2019 Category: Research Source Type: news
Boehringer Ingelheim and Lilly announce the CAROLINA(R) cardiovascular outcome trial of Tradjenta(R) met its primary endpoint of non-inferiority compared with glimepiride
Tradjenta (linagliptin) demonstrated no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk
With a median follow-up of more than 6 years, CAROLINA adds evidence to the long-term safety profile o... Biopharmaceuticals, Endocrinology Eli Lilly, Boehringer Ingelheim, Tradjenta, linagliptin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2019 Category: Pharmaceuticals Source Type: news
Duetact (Pioglitazone Hydrochloride and Glimepiride Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 10, 2018 Category: Drugs & Pharmacology Source Type: news
Amaryl Tablets (Glimepiride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 4, 2017 Category: Drugs & Pharmacology Source Type: news
